Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) EPS (Weighted Average and Diluted) (2021 - 2025)

Abvc Biopharma (ABVC) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.16 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 220.0% year-over-year to -$0.16, compared with a TTM value of -$0.44 through Dec 2025, up 2.22%, and an annual FY2025 reading of -$0.39, up 7.14% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.16 for Q4 2025 at Abvc Biopharma, down from -$0.09 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.25 in Q4 2022 and bottomed at -$1.19 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.01, with a median of -$0.09 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 1125.87% in 2022, then plummeted 2261.2% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.32 in 2021, then soared by 1125.87% to $3.25 in 2022, then crashed by 55.9% to $1.43 in 2023, then tumbled by 103.49% to -$0.05 in 2024, then crashed by 220.0% to -$0.16 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ABVC at -$0.16 in Q4 2025, -$0.09 in Q3 2025, and -$0.13 in Q2 2025.